Medical therapy for pulmonary arterial hypertension

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 1, 2008, Pages 65-81

  Driscoll, James A ^a   Chakinala, Murali M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ambrisentan; Bosentan; Endothelial progenitor cell; Endothelin receptor antagonist; Epoprostenol; Iloprost; Phosphodiesterase 5 inhibitor; Platelet derived growth factor inhibitor; Pulmonary arterial hypertension; Rho kinase inhibitor; Selective serotonin re uptake inhibitor; Sildenafil; Sitaxsentan; Treprostinil

Indexed keywords

AMBRISENTAN; AMLODIPINE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; INFLUENZA VACCINE; NIFEDIPINE; NITRATE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PNEUMOCOCCUS VACCINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SITAXSENTAN; SORAFENIB; TADALAFIL; UNINDEXED DRUG; UNIPROST; WARFARIN;

ADD ON THERAPY; AEROBIC EXERCISE; AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CELL BASED GENE THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ESSENTIAL HYPERTENSION; FACE PAIN; FLUSHING; GENE MUTATION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPOTENSION; INFLUENZA; INJECTION SITE PAIN; INSOMNIA; LEG PAIN; LIFESTYLE MODIFICATION; LOBAR PNEUMONIA; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PERIPHERAL EDEMA; PREDICTION; PRIMARY PREVENTION; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SODIUM RESTRICTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TERATOGENICITY; TREATMENT OUTCOME; TRISMUS; VACCINATION;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; EPOPROSTENOL; EXERCISE THERAPY; EXPERT TESTIMONY; HEALTH BEHAVIOR; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PULMONARY ARTERY; RECEPTOR, ENDOTHELIN A;

EID: 39049140608     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.1.65     Document Type: Review

References (129)

1. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):S5-S12
2. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):S13-S24
3. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995;8(12):2129-38
4. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002;45(3):173-202
5. Herve P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001;22(3):451-8
6. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37(10):741-5
7. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001;68(1):92-102
8. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001;195(3):367-74
9. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114(6):464-9
10. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328(24):1732-9
11. Peacock AJ, Dawes KE, Shock A, et al. Endothelin-1 and endothetin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 1992;7(5):492-9
12. Janakidevi K, Fisher MA, Del Vecchio PJ, et al. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 1992;263(6 Pt 1):C1295-C1301
13. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99(3):249-54
14. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible fbr pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108(8):1141-50
15. Christman BW, Mcpherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327(2):70-5
16. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159(6):1925-32
17. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333(4):214-21
18. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111(9):1339-46
19. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115(5):343-9
20. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173(9):1023-30
21. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29(4):515-24
22. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV cohort study. Am J Respir Crit Care Med 1997; 155(3):990-5
23. Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11(9):1107-11
24. Diller GP, Dimopoulos K Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006;27(14):1737-42
25. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40(4):780-8
26. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161(2 Pt 1):487-92
27. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996;334(5):296-302
28. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension Circulation 2006; 114(13):1417-31
29. Naeije R, Vachiéry JL. Medical therapy of pulmonary hypertension. Conventional therapies. Clin Chest Med 2001;22(3):517-27
30. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114(14):1482-9
31. Weiss BM, Zemp L, Seifert B. et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998;31(7):1650-7
32. Ramakrishna G, Sprung J, Ravi BS, et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005;45(10):1691-9
33. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):S35-S62
34. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70(4):580-7
35. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327(2):76-81
36. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006;28(5):999-1004
37. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111(23):3105-11
38. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):S56-S61
39. McLaughlin VV, Shillington A. Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106(12):1477-82
40. Badesch DB, Tapson VF, Mcgoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132(6):425-34
41. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99(14):1858-65
42. McLaughlin VV, Channick RN, Robbins IM, et al. Pulmonary hypertension roundtable: recapping 5 years, exploring emerging approaches. Adv Pulm Hypertens 2006;5(4):32-9
43. Remodulin® (treprostinil sodium) package insert. United Therapeutics Corp., Research Triangle Park, NC, USA; March 2006
44. Laliberte K Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44(2):209-14
45. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48(8):1672-81
46. Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006;48(7):1433-7
47. FREEDOM-M. Oral treprostinil as monotherapy for the treatment of pulmonary arterial hypertension (PAH) 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00325403
48. FREEDOM-C. Oral treprostinil in combination with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase-5 (PDE-5) inhibitor for the treatment of pulmonary arterial hypertension (PAH) 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00325442
49. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129(6):1636-43
50. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28(6):1195-203
51. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4
52. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006;129(3):683-8
53. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;172(12):1586-9
54. Tapson VF. Advances in prostanoid therapy: new studies, new methods of delivery. Adv Pulm Hypertens 2006;5(4):18-22
55. Centers for disease control and prevention (CDC): bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007;56(8):170-2
56. Ventavis® (iloprost) inhalation solution package insert. CoTherix, Inc., South San Francisco, CA, USA, Jan 2006
57. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9
58. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342(25):1866-70
59. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28(4):691-4
60. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26(18):1895-902
61. Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39(9):1496-502
62. Barst RJ, Mcgoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2119-25
63. Channick RN, Simonneau G, Sirbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288):1119-23
64. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903
65. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25(2):244-9
66. Efficacy and safety of oral bosentan in pulmonary arterial hypertension class II. Available from: http://clinicaltrials.gov/ct/show/NCT00091715 (2007)
67. Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):S62-S67
68. Tracleer® (bosentan tablets) package insert. Actelion Pharmaceuticals US, Inc. Feb 2007
69. Newman JH. Treatment of primary pulmonary hypertension - the next generation. N Engl J Med 2002;346(12):933-5
70. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46(3):529-35
71. Letaires® (ambrisentan) package insert. Gilead Sciences, Inc. Foster City, CA, USA; June 2007
72. Barst RJ, Langleben D, Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169(4):441-7
73. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47(10):2049-56
74. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 2006;12(27):3485-94
75. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44(7):1488-96
76. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105(20):2398-403
77. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43(7):1149-53
78. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20):2148-57
79. Galie N. Burgess G, Parpia T, et al. Effects of sildenafil on 1-year survival of patients with idiopathic pulmonary arterial hypertension. Abstract at the American Thoracic Society International Conference; 2005; San Diego, CA [Abs A802]
80. Revatio®(sildenafil citrate) tablets Package insert. Pfizer, Inc., New York, NY, USA, July 2006
81. Affuso F, Palmieri EA, Di Conza P, et al. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 2006;108(3):429-31
82. Palmieri EA, Affuso F, Fazio S, et al. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004;141(9):743-4
83. PHIRST-1: Tadatafil in the treatment of pulmonary arterial hypertension 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00125918
84. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26(5):858-63
85. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24(3):353-9
86. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174(11):1257-63
87. Clinical investigation into inhaled treprostinil sodium in patients with severe pulmonary arterial hypertension (PAH) (TRIUMPH) 2007. Available from: www.clinicaltrials.gov/ct/show/NCT00147199
88. Wilkens H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104(11):1218-22
89. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42(1):158-64
90. The "VISION" trial: ventavis inhalation with sildenafil to improve and optimize pulmonary arterial hypertension 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00302211
91. Simonneau G, Burgess G, Collings L, et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension. Abstract the American Thoracic Society International Conference; San Diego, CA; 2006; [Abstract A58]
92. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24(6):1007-10
93. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007;29(3):469-75
94. Assess the efficacy and safety of sildenafil when added to bosentan in the treatment of pulmonary arterial hypertension 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00323297
95. Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension (PAH) 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00303459
96. Paul GA, Gibbs JS, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60(1):107-12
97. Yu Y, Sweeney M, Zhang S, et al. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol 2003;284(2):C316-C330
98. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115(10):2811-21
99. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegativc patients. Eur Respir J 1998;11(3):554-9
100. Gleevec®(imatinib mesylate) package insert. Novartis Pharma Stein AG, Stein, Switzerland; 2006
101. Ghofrani HA, Seeger W, Grimminger F. Imainib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353(13):1412-13
102. Souza R, Sitbon O, Parent F, et al. Long-term imatinib treatment in pulmonary arterial hypertension. Thorax 2006;61(8):736
103. Safety and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00477269
104. Sorafenib stud: dosing in patients with pulmonary arterial hypertension (PAH) (2007). Available from: http://www.clinicaltrials.gov/ct/show/ NCT00452218
105. Eddahibi S, Hanoun N, Lanfumey L, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000;105(11):1555-62
106. MacLean MR, Deuchar GA, Hicks MN, et al. Overexpression of the 5-hydroxytrypramine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004;109(17):2150-5
107. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003;168(4):487-93
108. Guignabert C, Raffestin B, Benferhat R. et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005;111(21):2812-19
109. Kawut SM, Horn EM, Berekashvili KK, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006;19(5):370-4
110. Serotonin tran porter inhibitor escitalopram in pulmonary hypertension 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT0019O333
111. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005;25(9):1767-75
112. Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287(4):L656-L664
113. Nagaoka T, Fagan KA. Gebb SA, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171(5):494-9
114. Li F, Xia W, Li A, et al. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Pharmacol Res 2007;55(1):64-71
115. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94(3):385-93
116. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal prolifieration and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166(10):1403-8
117. Nishimura T, Vaszar LT. Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108(13):1640-5
118. Girgis RE, Li D, Zhan X et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003;285(3):H938-H945
119. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007
120. Simvastatin as a treatment for pulmonary hypertension 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00180713
121. Zhao YD, Courtman DW, Deng Y, et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96(4):442-50
122. Kanki-Horimoto S, Horimoto H, Mieno S, et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 2006; 1 14(1 Suppl):I181-I185
123. Nagaya N, Kangawa K, Kanda M, et al. Hybrid cell-gene therapy fbr pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003;108(7):889-95
124. Pulmonary hypertension: assessment of cell therapy (PHACeT) 2007. Available firom: http://www.clinicaltrials.gov/ct/show/NCT00469027
125. Gomberg-Maitland M, Huo D, Benza RL, et al. Creation of a model comparing 6-min walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant 2007;26(7):732-8
126. Van Wolferen SA, Marcus JT, Boonstra A. et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28(10):1250-7
127. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Cirulation 2002;106(3):319-24
128. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034-41
129. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70